GABA (gamma-aminobutyric acid) is the main neurotransmitter regulating sleep. The majority of drugs presently in use for the treatment of sleep disorders act by enhancing GABAergic neuronal inhibition. The GABA system is, therefore, of prime clinical relevance for the therapy of insomnia.

The focus of this volume is on the neuropsychopharmacology and the clinical impact of the GABA system in regulating sleep and wakefulness. It presents molecular, neuropharmacological, systems-biological and clinical approaches to the understanding of the mechanism of action of GABA and GABAergic drugs. It also explores the role of GABA in the basic drives that affect sleep, and the influences that adapt sleep and wakefulness to external events.

The Gaba Receptors, Third Edition, presents a critical appraisal of our current understanding of the molecular, behavioral, biochemical, clinical, and pharmacological properties of GABA receptors. Emphasis is placed on exploring cutting-edge findings on the structureal properties of receptor sites, mechanisms of receptor expression, chemical agents that differentiate receptor subtypes, and phenotypes displayed by GABA receptor null mice. Chapters in this updated and expanded edition examine such topics as GABA receptor subypes, trafficking postsynaptic GABA receptors, GABA receptor mutations associated with idiopathic generalized epilepsies and febrile seizures, and GABA receptors as a potential therapeutic target.

The Gaba Receptors, Third Edition, presents a critical appraisal of our current understanding of the molecular, behavioral, biochemical, clinical, and pharmacological properties of GABA receptors. Emphasis is placed on exploring cutting-edge findings on the structureal properties of receptor sites, mechanisms of receptor expression, chemical agents that differentiate receptor subtypes, and phenotypes displayed by GABA receptor null mice. Chapters in this updated and expanded edition examine such topics as GABA receptor subypes, trafficking postsynaptic GABA receptors, GABA receptor mutations associated with idiopathic generalized epilepsies and febrile seizures, and GABA receptors as a potential therapeutic target.

GABA (gamma-aminobutyric acid) is the main neurotransmitter regulating sleep. The majority of drugs presently in use for the treatment of sleep disorders act by enhancing GABAergic neuronal inhibition. The GABA system is, therefore, of prime clinical relevance for the therapy of insomnia. The focus of this volume is on the neuropsychopharmacology and the clinical impact of the GABA system in regulating sleep and wakefulness. It presents molecular, neuropharmacological, systems-biological and clinical approaches to the understanding of the mechanism of action of GABA and GABAergic drugs. It also explores the role of GABA in the basic drives that affect sleep, and the influences that adapt sleep and wakefulness to external events.

Highlighting the current developments and future directions in GABA and glycine research, this volume covers the major inhibitory neurotransmitters from the molecular mechanisms of signal transduction to their role in health and disease. It is of topical importance because these neurotransmitters are essential for brain function and therapy of diseases such as anxiety disorders, insomnias, epilepsy, depression, spasticity, and memory deficits. Distinguished scientists at the forefront of research contributed reviews on the role of these transmitters in governing neuronal networks, their signalling pathways, their receptors, the pharmacology of GABA A- and GABA B- and GABA C-receptors as well as of GABA- and glycine-transporters, and their role in disease. The volume serves as reference for pharmacologists/toxicologists, neuroscientists, neurologists and psychiatrists.